PBM vs LSCC

Lattice Semiconductor Corporation (LSCC) offers the better valuation at 5703.

6x trailing P/E (121. 1x forward), making it the more compelling value choice. Analysts rate Lattice Semiconductor Corporation (LSCC) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Lattice Semiconductor Corporation (LSCC) delivered a total return of +172.

4%, compared to -100. 0% for Psyence Biomedical Ltd. (PBM). Over 10 years, the gap is even starker: LSCC returned +23. 5% versus PBM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lattice Semiconductor Corporation (LSCC) is the lower-risk stock at 2.

40β versus Psyence Biomedical Ltd. 's 3. 42β — meaning PBM is approximately 42% more volatile than LSCC relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Lattice Semiconductor Corporation grew EPS -94.

9% year-over-year, compared to -1126. 6% for Psyence Biomedical Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lattice Semiconductor Corporation (LSCC) is the more profitable company, earning 0.

6% net margin versus 0. 0% for Psyence Biomedical Ltd. — meaning it keeps 0. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LSCC leads at 2. 9% versus 0. 0% for PBM. At the gross margin level — before operating expenses — LSCC leads at 68. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lattice Semiconductor Corporation (LSCC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Psyence Biomedical Ltd. (PBM) carries a higher beta of 3. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LSCC: +23. 5%, PBM: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PBM (Healthcare) and LSCC (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.